Therapeutic Cancer Vaccination with Immunopeptidomics-Discovered Antigens Confers Protective Antitumor Efficacy.

Peltonen K, Feola S, Umer HM, Chiaro J, Mermelekas G, Ylösmäki E, Pesonen S, Branca RMM, Lehtiö J, Cerullo V

Cancers (Basel) 13 (14) - [2021-07-07; online 2021-07-07]

Knowledge of clinically targetable tumor antigens is becoming vital for broader design and utility of therapeutic cancer vaccines. This information is obtained reliably by directly interrogating the MHC-I presented peptide ligands, the immunopeptidome, with state-of-the-art mass spectrometry. Our manuscript describes direct identification of novel tumor antigens for an aggressive triple-negative breast cancer model. Immunopeptidome profiling revealed 2481 unique antigens, among them a novel ERV antigen originating from an endogenous retrovirus element. The clinical benefit and tumor control potential of the identified tumor antigens and ERV antigen were studied in a preclinical model using two vaccine platforms and therapeutic settings. Prominent control of established tumors was achieved using an oncolytic adenovirus platform designed for flexible and specific tumor targeting, namely PeptiCRAd. Our study presents a pipeline integrating immunopeptidome analysis-driven antigen discovery with a therapeutic cancer vaccine platform for improved personalized oncolytic immunotherapy.

Global Proteomics and Proteogenomics [Technology development]

PubMed 34298622

DOI 10.3390/cancers13143408

Crossref 10.3390/cancers13143408

pii: cancers13143408
pmc: PMC8306067